3区 · 综合性期刊
ArticleOA
作者: Aneheim, Emma ; Lindegren, Sture ; Chammas, Roger ; Jacobsson, Lars ; Washiyama, Kohshin ; Machado, Camila Maria L ; Horta, Bruno Brasil ; Buchpiguel, Carlos ; Cederkrantz, Elin ; Albertsson, Per ; Moro, Ana Maria ; Bäck, Tom ; Andrade, Luciana N S ; Jensen, Holger ; Okamoto, Oswaldo Keith ; Palm, Stig ; Tuma, Maria Carolina B ; Hultborn, Ragnar
The aim of this preclinical study was to evaluate the characteristics of the monoclonal antibody Rebmab200, which is a humanized version of the ovarian-specific murine antibody MX35. This investigation contributes to the foundation for future clinical α-radioimmunotherapy of minimal residual ovarian cancer with 211At-Rebmab200. Here, the biodistribution of 211At-Rebmab200 was evaluated, as was the utility of 99mTc-Rebmab200 for bioimaging. Rebmab200 was directly compared with its murine counterpart MX35 in terms of its in-vitro capacity for binding the immobilized NaPi2B epitope and live cells; we also assessed its biodistribution in nude mice carrying subcutaneous OVCAR-3 tumors. Tumor antigen and cell binding were similar between Rebmab200 and murine MX35, as was biodistribution, including normal tissue uptake and in-vivo tumor binding. We also demonstrated that 99mTc-Rebmab200 can be used for single-photon emission computed tomography of subcutaneous ovarian carcinomas in tumor-bearing mice. Taken together, our data support the further development of Rebmab200 for radioimmunotherapy and diagnostics.
